StockData
Sinovac Biotech Ltd logo

Sinovac Biotech Ltd (SVA) stock

SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026Score 7/30
$6.47+0.00 (0.00%)

Close on Nov 17, 2026Market cap $464.94MP/E –Yield 850.08%

Sinovac Biotech operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -$490.13M. The highest annual figure on record is $17.62B in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$490.13M–
FY2024Dec 31, 2024-$505.54M–
FY2023Dec 31, 2023-$713.98M–
FY2022Dec 31, 2022-$508.99M-102.9%
FY2021Dec 31, 2021$17.62B+8070.1%
FY2020Dec 31, 2020$215.64M+214.5%
FY2019Dec 31, 2019$68.56M+51.3%
FY2018Dec 31, 2018$45.32M-0.2%
FY2017Dec 31, 2017$45.42M+8911.3%
FY2016Dec 31, 2016$504.00K-86.4%
FY2015Dec 31, 2015$3.70M+96.0%
FY2014Dec 31, 2014$1.89M-81.0%
FY2013Dec 31, 2013$9.95M–
FY2012Dec 31, 2012-$21.15M-726.9%
FY2011Dec 31, 2011$3.37M–
FY2010Dec 31, 2010-$13.36M-131.7%
FY2009Dec 31, 2009$42.15M–

More Sinovac Biotech figures

See a number that looks wrong?